Sunday, July 02, 2023 11:34:26 PM
Sarepta will be fine. I expect the strange people at the FDA to take another look at us in September/October and some are suggesting they will end the trial early (it will be finished in effect at that point anyway) due to unambiguous success seen ... and approve the drug for all ages - as they apparently told our CEO a few months ago would be "the label" upon any formal approval - which was expected to be early next year or late this year. But, as i say, some expect they take an October re-look at the trial and accept it's success and expand the label then and there. That will bring the stock to 200 more or less. That will unleash the dam and we can move on to other things, finally. Check out the Investor village board for more of my ranting and raving if you dare. Otherwise, maybe you can explore any other Sarepta boards - stocktwits? reddit? for me too .... and if you find one that's wiggling a bit more than this one (!) or IV, let me know...with links. (I'm pretty lame. I had a hard time finding this one again just now!) Thanks and all should be well now with Sarepta, finally.
Maybe there's someone here who can correct or expand on my info for newbie Mr. K's benefit. And to exercise your fingers a bit as well!
Recent SRPT News
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health • Business Wire • 05/03/2024 02:07:00 PM
- Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments • Business Wire • 05/01/2024 08:05:00 PM
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 10:38:00 PM
- Sarepta Therapeutics to Announce First Quarter 2024 Financial Results • Business Wire • 04/24/2024 12:30:00 PM
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/29/2024 08:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:38:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 01:00:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 01:00:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 01:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 01:00:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:07 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 10:34:59 PM
- Sarepta Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 03/04/2024 01:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2024 12:55:21 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM